Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of ...

European shares dipped to a more than one-week low as investors reacted to corporate reports and U.S. tariffs impacting sectors like automotives and beverages. Companies like Ferrari and Sanofi saw ...